WOCKPHARMA
Wockhardt
Each stock's 10,000-path forecast, rendered as light.
Wockhardt (WOCKPHARMA) Stock Analysis & Case Study
Is WOCKPHARMA a good buy? The data-driven verdict.
Wockhardt (WOCKPHARMA) trades at ₹2,014,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, Wockhardt (WOCKPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 115.0× earnings, ROE of 6.1%, a 80% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
WOCKPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is WOCKPHARMA overvalued? WOCKPHARMA P/E vs its sector
WOCKPHARMA's P/E of 115.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
WOCKPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of WOCKPHARMA history (62%/yr drift, 55%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| WOCKPHARMA 2027 | ₹1,580 | ₹3,253 | ₹6,523 | +62% |
| WOCKPHARMA 2028 | ₹1,868 | ₹5,082 | ₹14,251 | +153% |
| WOCKPHARMA 2029 | ₹2,381 | ₹8,117 | ₹28,719 | +304% |
| WOCKPHARMA 2030 | ₹3,201 | ₹13,171 | ₹54,273 | +555% |
| WOCKPHARMA 2031 | ₹4,341 | ₹20,901 | ₹1,02,121 | +939% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability WOCKPHARMA goes up, or doubles?
The bull case for WOCKPHARMA
- A 10,000-path probability model puts a 80% chance the price is higher in a year, with a median target of ₹3,253 (+62%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹28,719.
The bear case & risks
- A rich 115.0× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 6.1%, capital efficiency trails higher-quality peers.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- High historical volatility (55%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,381.
WOCKPHARMA volatility & expected range, how bumpy is the ride?
Over the last 2.0 years WOCKPHARMA compounded at 62%/year with annualized volatility of 55%. That volatility implies a 1-year 80% range of ₹1,580–₹6,523, the honest backbone behind any single price target.
WOCKPHARMA price forecast, the full 60-month probability fan
WOCKPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds WOCKPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the WOCKPHARMA price target & forecast page.
WOCKPHARMA Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. WOCKPHARMA scores 3/9,weak on the financial-strength checks.
WOCKPHARMA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy WOCKPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 40.1% | 2.5× |
| Groww | 40.2% | 2.5× |
Compare every broker on the WOCKPHARMA MTF page.
WOCKPHARMA vs peers,sector comparison
About Wockhardt: sector, index & market-cap context
Wockhardt (WOCKPHARMA) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹32,727 Cr. See more Nifty 100 stocks.
How the WOCKPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Wockhardt's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
WOCKPHARMA analysis, FAQs
Is Wockhardt (WOCKPHARMA) a good buy?
On the numbers, Wockhardt (WOCKPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 115.0× earnings, ROE of 6.1%, a 80% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is WOCKPHARMA overvalued or undervalued?
WOCKPHARMA trades at 115.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the WOCKPHARMA share price target for 2031?
WOCKPHARMA's probability-weighted 2031 median target is ₹20,901, with an 80% range of ₹4,341–₹1,02,121 (10,000-path Monte-Carlo).
What is the probability WOCKPHARMA doubles in 5 years?
The modelled probability of WOCKPHARMA reaching ₹4,022 (2×) within 5 years is 91%.
What is the bull case for WOCKPHARMA?
A 10,000-path probability model puts a 80% chance the price is higher in a year, with a median target of ₹3,253 (+62%).
What are the risks in WOCKPHARMA?
A rich 115.0× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 6.1%, capital efficiency trails higher-quality peers. A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.